GLP-1 stands for glucagon-like peptide-1, an incretin hormone naturally produced in the gut
Elsawa SF, Novak AJ, Grote D, Konopleva M, Andreeff M , Witzig TE, Ansell SM
Kennedy, for one, has been vocally against the pharma industrys solutions to obesity, arguing instead that the focus should be on obesity prevention through healthy, non-processed foods and exercise
GLP-1 agonists or drugs can mimic these natural functions in people with insulin resistance
Patients experiencing these changes should not automatically assume their medication has failed but should consult their healthcare provider for systematic evaluation
This is crucial, given the strong link between MASH and cardiovascular, metabolic, and renal conditions, where semaglutide has already shown established health benefits. MASH is closely linked to metabolic risk factors like obesity, type 2 diabetes, and high blood pressure